Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
On February 26, 2024, STENOCARE A/S ("Stenocare") announced, that it had received approval to supply a new THC/CBD medical cannabis oil product under the Danish Pilot Programme. Starting today the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot. Out of the many suppliers seeking approval to sell their products, Stenocare has been in a clear leadership position from the start of the Pilot in 2018 and is the only supplier of three different medical cannabis oil products under the Pilot.
Sales can begin: STENOCARE has successfully imported the first batch of a new medical cannabis oil product into Denmark. The new product is a combination THC/CBD oil containing 15 mg/ml THC and 24 mg/ml CBD with dosing delivered via an oral syringe. The new product is available starting today via pharmacies and requires a prescription.
Strong product portfolio: Stenocare is the first and so far, only supplier of this THC/CBD oil product for the Danish Pilot Programme. With this, Stenocare now once again has the complete portfolio of three medical cannabis oil products (ie. THC30 oil, CBD20 oil and now the THC/CBD oil). With this new product, Stenocare is able to offer the complete range of oil products they successfully sold to patients during 2018 and 2019, that grew the company sales and allowed the Company to reach breakeven in Q1 2019. Therefore, having this complete product range for the Danish Pilot Programme is an important element in the 2024 ambitions to once again reach breakeven at the end of the year.
Stenocare CEO Thomas Skovlund Schnegelsberg comments:
"Today we make yet another medical cannabis oil product available for patients. We now offer three different oil products, that together are addressing therapeutic needs across several illnesses. There are significant investments in regulatory work and documentation to have these products approved under the Danish Pilot Programme, and today's milestone is another proof point for the unique skills and experiences of our regulatory team to meet the strict requirements of the Danish Medicines Agency. This fortifies Stenocare's leading position in the Danish market."